Persistence of rabies antibody 3 years after postexposure prophylaxis with 2-1-1 regimen of Vero-cell rabies vaccine for human use and antibody response to two booster doses

HUANG Zhu-hang; SU Jia-li; ZHENG Hui-zhen; ZHANG Yi-bin; TANG Yan; XIA Yan-hui; CHEN Yi-jian; ZHANG Lei; FAN Ren-feng; ZHANG Ji-kai

doi:10.16462/j.cnki.zhjbkz.2019.05.023

Volume 23 Issue 5

May 2019

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2019 > 23(5): 607-612

HUANG Zhu-hang, SU Jia-li, ZHENG Hui-zhen, ZHANG Yi-bin, TANG Yan, XIA Yan-hui, CHEN Yi-jian, ZHANG Lei, FAN Ren-feng, ZHANG Ji-kai. Persistence of rabies antibody 3 years after postexposure prophylaxis with 2-1-1 regimen of Vero-cell rabies vaccine for human use and antibody response to two booster doses[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2019, 23(5): 607-612. doi: 10.16462/j.cnki.zhjbkz.2019.05.023

Citation:

HUANG Zhu-hang, SU Jia-li, ZHENG Hui-zhen, ZHANG Yi-bin, TANG Yan, XIA Yan-hui, CHEN Yi-jian, ZHANG Lei, FAN Ren-feng, ZHANG Ji-kai. Persistence of rabies antibody 3 years after postexposure prophylaxis with 2-1-1 regimen of Vero-cell rabies vaccine for human use and antibody response to two booster doses[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2019, 23(5): 607-612. doi: 10.16462/j.cnki.zhjbkz.2019.05.023

Citation:

HUANG Zhu-hang, SU Jia-li, ZHENG Hui-zhen, ZHANG Yi-bin, TANG Yan, XIA Yan-hui, CHEN Yi-jian, ZHANG Lei, FAN Ren-feng, ZHANG Ji-kai. Persistence of rabies antibody 3 years after postexposure prophylaxis with 2-1-1 regimen of Vero-cell rabies vaccine for human use and antibody response to two booster doses[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2019, 23(5): 607-612. doi: 10.16462/j.cnki.zhjbkz.2019.05.023

PDF( 817 KB)

Persistence of rabies antibody 3 years after postexposure prophylaxis with 2-1-1 regimen of Vero-cell rabies vaccine for human use and antibody response to two booster doses

doi: 10.16462/j.cnki.zhjbkz.2019.05.023

1.
Guangdong Provincial Institute of Biological Products and Materia Medica, Department of Biological Products Surveillance and Evaluation, Guangzhou 510440, China
2.
Guangdong Provincial Center for Disease Control and Prevention, Institute for Infectious Disease Control and Prevention, Guangzhou 511430, China
3.
Liaoning Chengda Biological Limited by Share Ltd, Department of Medical Market, Shenyang 110179, China

Funds:

Guangdong technology service platform for clinical research on vaccines Guangdong provincial development and reform commission[2016] No. 779

Guangdong province laboratory system construction special funds Guangdong province vaccine safety key scientific research base, 2012A061300003

Guangzhou vaccine safety evaluation of key laboratory special funds 2014SY000009

Guangdong province medical science and technology research fund project B2016009

More Information

Corresponding author: ZHANG Ji-kai, E-mail: 527929822@qq.com
Received Date: 2018-11-28
Rev Recd Date: 2019-03-17
Publish Date: 2019-05-10

Abstract

Abstract

Objective To evaluate the antibody persistence following rabies postexposure prophylaxis (PEP) with 2-1-1 regimen and antibody response to two booster doses. Methods A total of 314 healthy volunteers at year 1, year 2, year 3 who had received a complete rabies PEP using 2-1-1 regimen were recruited. Two booster doses of rabies vaccine were inoculated, and blood samples were obtained before and 14 days after two booster doses. Human rabies virus IgG antibody was evaluated by ELISA, and the antibody levels and antibody positive rates were analyzed. Results The antibody GMC of 303 people at year 1, year 2, year 3 after a complete immunization was 1.33 IU/mL, 1.04 IU/mL and 0.72 IU/mL, with an antibody positive rate of 77.78%, 66.67% and 55.56%, respectively. Among 282 people who received 2 doses for booster immunization, the antibody GMC at day 14 of 1 year, 2 year and 3 year immunization group was 16.83 IU/mL, 19.37 IU/mL and 21.05 IU/mL respectively, which was higher than that before booster immunization (t=16.54, P < 0.001; t=13.85, P < 0.001; t=16.02, P < 0.001). The antibody positive rate was 100.00%, 99.00% and 100.00%, respectively. Conclusions The immune persistence of rabies antibody after PEP with antirabies vaccine using the 2-1-1 regimen is good so as to the immune response after 2 doses of booster immunization in 3 years is effective.
- Rabies,
- 2-1-1 regimen,
- Persistence

FullText(HTML)

References(15)

References

[1]	WHO. Rabies vaccines: WHO position paper-April 2018[J]. Wkly Epidemiol Rec, 2018, 16: 201-220. http://www.sciencedirect.com/science/article/pii/S0264410X18309022
[2]	杨娟, 赖圣杰, 余宏杰. 感染性疾病流行现状、防控挑战与应对[J]. 中华疾病控制杂志, 2017, 21(7): 647-649, 674. DOI: 10.16462/j.cnki.zhjbkz.2017.07.001. Yang J, Lai SJ, Yu HJ. Epidemiological status, challenge of prevention and control, and response strategy of infectious diseases[J]. Chin J Dis Control Prev, 2017, 21(7): 647-649, 674. DOI: 10.16462/j.cnki.zhjbkz.2017.07.001.
[3]	周航, 李昱, 陈瑞丰, 等. 狂犬病预防控制技术指南(2016版)[J]. 中华流行病学杂志, 2016, 37(2): 139-163. DOI: 10.3760/cma.j.issn.0254-6450.2016.02.001. Zhou H, Li Y, Chen RF, et al. Technical guideline for human rabies prevention and control(2016)[J]. Chin J Epidemiol, 2016, 37(2): 139-163. DOI: 10.3760/cma.j.issn.0254-6450.2016.02.001.
[4]	Zhou H, Vong S, Liu K, et al. Human rabies in China, 1960-2014: a descriptive epidemiological study[J]. PLoS Negl Trop Dis, 2016, 10(8): e0004874. DOI: 10.1371/journal.pntd.0004874.
[5]	Liu HZ, Huang GH, Tang Q, et al. The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen[J]. Hum Vaccin, 2011, 7(2): 220-224. DOI: 10.4161/hv.7.2.14003.
[6]	Li R, Li Y, Wen S, et al. Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study[J]. Hum Vaccin Immunother, 2015, 11(2): 435-442. DOI: 10.4161/21645515.2014.994460.
[7]	Wang J, Luo FJ, Feng Z, et al. Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above[J]. Hum Vaccin Immunother, 2017, 13(1): 144-150. DOI: 10.1080/21645515.2016.1230260.
[8]	Ren J, Yao L, Sun J, et al. Zagreb regimen, an abbreviated intramuscular schedule for rabies vaccination[J]. Clin Vaccine Immunol, 2015, 22(1): 1-5. DOI: 10.1128/CVI.00531-14.
[9]	陈伟, 郑新雄, 张隆明, 等. 冻干无佐剂Vero细胞CTN狂犬病疫苗安全性和免疫原性研究[J]. 中华流行病学杂志, 2009, 30(12): 1261-1264. DOI: 10.3760/cma.j.issn.0254-6450.2009.12.013. Chen W, Zheng XX, Zhang LL, et al. Evaluation on the safety and efficacy of lyophilized purified human rabies vaccine(CTN-Vero-RV)[J]. Chin J Epidemiol, 2009, 30(12): 1261-1264. DOI: 10.3760/cma.j.issn.0254-6450.2009.12.013.
[10]	钱晓华, 徐葛林, 吴志芳, 等. 国产无佐剂Vero细胞狂犬病疫苗接种后的不良反应及免疫持久性观察[J]. 中国生物制品学杂志, 2013, 26(10): 1467-1471. https://www.cnki.com.cn/Article/CJFDTOTAL-SWZP201310031.htm Qian XH, Xu GL, Wu ZF, et al. Adverse reactions and immune-persistence after immunization with domestic adjuvant-free rabies vaccine prepared with Vero cells[J]. Chin J Biologicals, 2013, 26(10): 1467-1471. https://www.cnki.com.cn/Article/CJFDTOTAL-SWZP201310031.htm
[11]	Zhang X, Zhu Z, and Wang C. Persistence of rabies antibody 5 years after postexposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose[J]. Clin Vaccine Immunol, 2011, 18(9): 1477-1479. DOI: 10.1128/CVI.05090-11.
[12]	朱加宏, 吴小红, 李玉华, 等. 人二倍体细胞狂犬病疫苗免疫8年后加强免疫效果研究[J]. 中华实验和临床病毒学杂志, 2018, 32(3): 233-236. DOI: 10.3760/cma.j.issn.1003-9279.2018.03.003. Zhu JH, Wu XH, Li YH, et al. Investigation on the effects of booster immunization of human diploid cell rabies vaccine after eight years of primary vaccination[J]. Chinese J Exp Clin Virol, 2018, 32(3): 233-236. DOI: 10.3760/cma.j.issn.1003-9279.2018.03.003.
[13]	Fayaz A, Simani S, Janani A, et al. Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV)[J]. Vaccine, 2011, 29(21): 3742-3745. DOI: 10.1016/j.vaccine.2011.03.048.
[14]	Shi N, Zhang Y, Zheng H, et al. Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects[J]. Hum Vaccin Immunother, 2017, 13(6): 1-8. DOI: 10.1080/21645515.2017.1279770.
[15]	于鹏程, 由淑珍, 卢学新, 等. RFFIT、FAVN、ELISA及狂犬病中和抗体检测试剂盒对狂犬病抗体检测的比较研究[J]. 病毒学报, 2017, 33(2): 265-268. DOI: 10.13242/j.cnki.bingduxuebao.003132. Yu PC, You SZ, Lu XX, et al. Comparative study on the detection of rabies antibodies using RFFIT, FAVN, ELISA and RVNA kits[J]. Chinese J Virol, 2017, 33(2): 265-268. DOI: 10.13242/j.cnki.bingduxuebao.003132.